Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Jaffray Cuts Price Target on Anthera Pharma (ANTH) to $10 Following 4Q
March 11, 2016 8:31 AM ESTPiper Jaffray maintained an Overweight rating on Anthera Pharma (NASDAQ: ANTH), and cut the price target to $10.00 (from $14.00), following the company's 4Q. Anthera stopped enrollment of the Phase II BRIGHT-SC trial of blisibimod at 57 IgA Nephropathy patients, of which 45 remained on study. Also, Anthera... More
Anthera Pharma (ANTH) Tops Q4 EPS by 10c
March 10, 2016 8:38 AM ESTAnthera Pharma (NASDAQ: ANTH) reported Q4 EPS of ($0.18), $0.10 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $1.92 million versus the consensus estimate of $150 thousand.
Cash and cash equivalents totaled $47 million as of December 31, 2015, compared to $2.6 million as of December 31,... More
